STOCKHOLM, SWEDEN – Vironova AB (publ), a leading Nano-Characterization technology and software company, announced the approval of a new US-patent application.
The patent cover topical administration against herpes with B-220 compound in U.S. (US2013310392).
“Problems with resistance and reactivation of the dormant infection need to be approached by implementing new innovations and providing alternative drug options. We are confident that Vironova will be at the forefront of the commercial pharmaceutical market to provide better solutions to treat the herpes simplex virus infections.” says Mohammed Homman, Founder and CEO of Vironova AB.
The approval of the US herpes-patent enables Vironova to further develop a pharmaceutical formulation for topical administration against herpes simplex virus comprising of the 2,3-dimethyl-6-(N,N-dimethylaminoethyl)-6H-indolo-[2,3-b] quinoxaline more commonly known as the B-220 compound.
With the approval, Vironova is now further advancing the development of an effective topical medical therapy for herpes cold sores in compliance with the US Food and Drug Administration (FDA) regulations.
About the B-220 compound.
Vironova’s B-220 lead compound in the approved US patent for topical administration against herpes was first discovered over 4 decades ago by Professor Jan Bergman who was sponsored to synthesize the compound by the Swedish pharmaceutical company Kabi.
B-220 and analogues of the compound are known to have a broad-spectrum anti-viral effect against all viruses tested from the herpesvirus group i.e. herpes simplex virus type (HSV-1) and type 2 (HSV-2), Cytomegalovirus (CMV) and Varicella zoster virus (VZV). B-220 appears to inhibit viral replication at different stages of the virus cycle compared to commercially available standard anti-herpes treatments containing acyclovir.
Acyclovir is the standard treatment option available today, however it is not a cure for herpes infections.
For further information please contact:
Head of Drug Development